Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study.

Abstract

OBJECTIVE:

To assess the efficacy and tolerability of etanercept to treat psoriatic arthritis.

MATERIALS AND METHODS:

A total of 1,122 patients who had active psoriatic arthritis were enrolled in a Phase 4, non-randomized, open-label, single-arm, 24-week study. These patients had clinically stable, plaque psoriasis involving >or=10% body surface area and joint disease (either >or=two swollen and >or=two tender/painful joints for >or=3 months, or >or=one joint with sacroiliitis or spondylitis). They received etanercept therapy 50 mg subcutaneously once weekly for 24 weeks.

RESULTS:

After 24 weeks of treatment, 865 patients (77.1%; 95% CI: 74.64-79.55%) achieved a 'mild or better' score on the physician global assessment of psoriasis and were improved from baseline. Mean improvement in body surface area involvement was 16.9 percentage points (15.89-17.91). Patient global assessment of psoriasis, joint pain, and joint disease scores were improved by means of 2.2 (2.15-2.34), 2.7 (2.53-2.84), and 1.5 (1.39-1.55), respectively. Thirty-five patients (3.1%) experienced at least one serious adverse event. No patient died during the study.

CONCLUSIONS:

These results support the effectiveness and tolerability of etanercept treatment in patients with psoriatic arthritis being treated at dermatology clinics.

• Authors: Alice B Gottlieb, Leon Kircik, Drore Eisen, J Mark Jackson, Erin E Boh, Bruce E Strober, Ellen Frankel, H Amt Xia, Seth R Stevens
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 17 Issue 6 Pg. 343-52 ( 2006) ISSN: 0954-6634 [Print] England
• PMID: 17853307 (Publication Type: Clinical Trial, Phase IV, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Immunoglobulin G
• Immunosuppressive Agents
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Arthritis, Psoriatic (diagnosis, drug therapy)
• Etanercept
• Female
• Humans
• Immunoglobulin G (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Male
• Middle Aged
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Treatment Outcome